Top

Published in:

01-01-2021 | Incretin Mimetics | Review Article

Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis

Authors: Shubing Jia, Zhiying Wang, Ruobing Han, Zinv Zhang, Yuping Li, Xiaotong Qin, Mingyi Zhao, Rongwu Xiang, Jingyu Yang

Published in: Acta Diabetologica | Issue 1/2021

Abstract

Purpose

Although there are many different methods of treating type 2 diabetes (T2D), it is still difficult to draw coincident conclusions concerning the efficacy and safety of different classes of new drugs, and the recommendation level of them has still kept uncertain as second anti-diabetic agents. Therefore, the aim of this study was to summarize evidence on the efficacy and safety of DPP-4is, GLP-1RAs and SGLT-2is as monotherapy or add-on to metformin (Met) for treatment of T2D.

Materials and methods

We searched PubMed, Embase, Cochrane library and ClinicalTrials.gov for relevant articles in keeping with established methods using terms associated with anti-diabetic agents up to February, 2020, with no start date restriction. Weighted mean difference and risk ratios with 95% confidence intervals were calculated within traditional and network meta-analysis. Primary outcomes were the mean change in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) change and the frequency of hypoglycemic events from baseline after 12 weeks of treatment.

Results

In total, 64 eligible studies comprising 37,780 patients and 7 treatment strategies were included. The results of primary outcomes showed that GLP-1RAs were significantly more effective than DPP-4is or SGLT-2is in reducing HbA1c when add-on to Met. For FPG, both GLP-1RAs and SGLT-2is significantly reduced FPG compared with DPP-4is whether add-on to Met or not. For hypoglycemia, monotherapy has a lower risk than combination therapy except for SGLT-2is. Ranking probability analysis indicated that GLP-1RAs and SGLT-2is, respectively, reduced HbA1c and FPG most when add-on to Met. Meanwhile, GLP-1RAs took the lowest risk to induce the hypoglycemia, whereas GLP-1RAs plus Met the highest.

Conclusions

Both GLP-1RAs and SGLT-2is have their own advantages in efficacy and safety. Monotherapy is beneficial for reducing the risk of hypoglycemia. The recommendation should be a patient-centered approach when selecting treatment choices.

Available only for authorised users

Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH et al (2017) IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024CrossRefPubMed

Aschner P (2017) New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract 132:169–170. https://doi.org/10.1016/j.diabres.2017.09.002CrossRefPubMed

Schernthaner G, Lavalle-Gonzalez FJ, Davidson JA, Jodon H, Vijapurkar U, Qiu R et al (2016) Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Postgrad Med 128(8):725–730. https://doi.org/10.1080/00325481.2016.1210988CrossRefPubMed

Davidson JA, Sloan L (2017) Fixed-dose combination of Canagliflozin and Metformin for the treatment of type 2 diabetes: an overview. Adv Ther 34(1):41–59. https://doi.org/10.1007/s12325-016-0434-2CrossRefPubMed

Gurgle HE, White K, McAdam-Marx C (2016) SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag 12:239–249. https://doi.org/10.2147/VHRM.S83088CrossRefPubMedPubMedCentral

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140–149. https://doi.org/10.2337/dc14-2441CrossRefPubMed

Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC (2014) Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 37(4):985–992. https://doi.org/10.2337/dc13-2097CrossRefPubMedPubMedCentral

de Wit HM, Te Groen M, Rovers MM, Tack CJ (2016) The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol 82(1):301–314. https://doi.org/10.1111/bcp.12925CrossRefPubMedPubMedCentral

Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696–1705. https://doi.org/10.1016/S0140-6736(06)69705-5CrossRefPubMed

10.

Tsimihodimos V, Filippatos TD, Elisaf MS (2017) Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opin Drug Metab Toxicol 13(4):399–408. https://doi.org/10.1080/17425255.2017.1258055CrossRefPubMed

11.

Busch RS, Kane MP (2017) Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med 129(7):686–697. https://doi.org/10.1080/00325481.2017.1342509CrossRefPubMed

12.

Kaneto H, Obata A, Shimoda M, Kimura T, Hirukawa H, Okauchi S et al (2016) Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs. Curr Med Chem 23(27):3044–3051. https://doi.org/10.2174/0929867323666160627102516CrossRefPubMed

13.

Wang ZY, Sun JH, Han RB, Fan DZ, Dong XY, Luan ZH et al (2018) Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 20(1):113–120. https://doi.org/10.1111/dom.13047CrossRefPubMed

14.

Hussein H, Zaccardi F, Dhalwani NN, Davies MJ, Khunti K, Gray LJ (2018) Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. BMJ Open 8(11):e023206. https://doi.org/10.1136/bmjopen-2018-023206

15.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097CrossRefPubMedPubMedCentral

16.

Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928CrossRefPubMedPubMedCentral

17.

Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C et al (2016) Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 388(10047):881–890. https://doi.org/10.1016/S0140-6736(16)30385-3CrossRefPubMed

18.

Higgins JPT, Green S (2017) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. http://handbook-5-1.cochrane.org/. Accessed 10 Oct 2017

19.

Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897–900. https://doi.org/10.1136/bmj.331.7521.897CrossRefPubMedPubMedCentral

20.

Salanti G, Ades AE, Ioannidis JPA (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163–171. https://doi.org/10.1016/j.jclinepi.2010.03.016CrossRefPubMed

21.

Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS ONE 8(10):e76654. https://doi.org/10.1371/journal.pone.0076654CrossRefPubMedPubMedCentral

22.

White IR, Barrett JK, Jackson D, Higgins JPT (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3(2):111–125. https://doi.org/10.1002/jrsm.1045CrossRefPubMedPubMedCentral

23.

Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JPT (2012) Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41(3):818–827. https://doi.org/10.1093/ije/dys041CrossRefPubMedPubMedCentral

24.

Rhodes KM, Turner RM, Higgins JPT (2015) Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol 68(1):52–60. https://doi.org/10.1016/j.jclinepi.2014.08.012CrossRefPubMedPubMedCentral

25.

Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G (2013) Evaluation of inconsistency in networks of interventions. Int J Epidemiol 42(1):332–345. https://doi.org/10.1093/ije/dys222CrossRefPubMed

26.

Tahrani AA, Barnett AH, Bailey CJ (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12(10):566–592. https://doi.org/10.1038/nrendo.2016.86CrossRefPubMed

27.

Ahren B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R (2013) Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 36(9):2543–2550. https://doi.org/10.2337/dc12-2006CrossRefPubMedPubMedCentral

28.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z (2014) Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 37(8):2149–2158. https://doi.org/10.2337/dc13-2761CrossRefPubMedPubMedCentral

29.

Zang L, Liu Y, Geng J, Luo Y, Bian F, Lv X et al (2016) Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Diabetes Obes Metab 18(8):803–811. https://doi.org/10.1111/dom.12674CrossRefPubMedPubMedCentral

30.

Frias JP, Guja C, Hardy E, Ahmed A, Dong F, Ohman P et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4(12):1004–1016. https://doi.org/10.1016/S2213-8587(16)30267-4CrossRefPubMed

31.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin Study 036 Group (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30(8):1979–1987. https://doi.org/10.2337/dc07-0627CrossRefPubMed

32.

DeFronzo RA, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S et al (2009) The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32(9):1649–1655. https://doi.org/10.2337/dc08-1984CrossRefPubMedPubMedCentral

33.

List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32(4):650–657. https://doi.org/10.2337/dc08-1863CrossRefPubMed

34.

Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study Group (2009) Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 63(1):46–55. https://doi.org/10.1111/j.1742-1241.2008.01933.xCrossRefPubMed

35.

Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K et al (2010) Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 27(12):1409–1419. https://doi.org/10.1111/j.1464-5491.2010.03131.xCrossRefPubMed

36.

Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R et al (2009) Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 11(6):611–622. https://doi.org/10.1111/j.1463-1326.2009.01056.xCrossRefPubMed

37.

DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE (2012) Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 97(5):1615–1622. https://doi.org/10.1210/jc.2011-2243CrossRefPubMed

38.

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM et al (2008) Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 24(2):537–550. https://doi.org/10.1185/030079908X260925CrossRefPubMed

39.

Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD et al (2010) Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 12(3):252–261. https://doi.org/10.1111/j.1463-1326.2009.01187.xCrossRefPubMed

40.

Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L et al (2011) The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 13(7):644–652. https://doi.org/10.1111/j.1463-1326.2011.01390.xCrossRefPubMed

41.

Scott R, Loeys T, Davies MJ, Engel SS, Sitagliptin Study 801 Group (2008) Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 10(10):959–969. https://doi.org/10.1111/j.1463-1326.2007.00839.xCrossRefPubMed

42.

Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA et al (2011) Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13(1):65–74. https://doi.org/10.1111/j.1463-1326.2010.01326.xCrossRefPubMed

43.

Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P et al (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376(9739):431–439. https://doi.org/10.1016/S0140-6736(10)60590-9CrossRefPubMed

44.

Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K et al (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35(6):1232–1238. https://doi.org/10.2337/dc11-1926CrossRefPubMedPubMedCentral

45.

Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF (2012) Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66(5):446–456. https://doi.org/10.1111/j.1742-1241.2012.02911.xCrossRefPubMed

46.

Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M et al (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4) a 26-week double-blind study. Diabetes Care 35(2):252–258. https://doi.org/10.2337/dc11-1107CrossRefPubMedPubMedCentral

47.

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S et al (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375(9724):1447–1456. https://doi.org/10.1016/S0140-6736(10)60307-8CrossRefPubMed

48.

Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z (2015) Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab 17(9):849–858. https://doi.org/10.1111/dom.12479CrossRefPubMedPubMedCentral

49.

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T et al (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15(12):1154–1160. https://doi.org/10.1111/j.1463-1326.2012.01593.xCrossRefPubMed

50.

Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R (2012) Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther 3(1):13. https://doi.org/10.1007/s13300-012-0013-8CrossRefPubMedPubMedCentral

51.

Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y et al (2014) Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 31(2):176–184. https://doi.org/10.1111/dme.12328CrossRefPubMed

52.

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ (2012) Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 14(6):565–574. https://doi.org/10.1111/j.1463-1326.2012.01590.xCrossRefPubMed

53.

Yang WY, Guan YF, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS et al (2012) The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 4(3):227–237. https://doi.org/10.1111/j.1753-0407.2012.00213.xCrossRefPubMed

54.

Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX et al (2013) Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-Emerge 7 Study). Obesity 21(2):238–247. https://doi.org/10.1002/oby.20042CrossRefPubMed

55.

Ahren B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C et al (2014) HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 37(8):2141–2148. https://doi.org/10.2337/dc14-0024CrossRefPubMed

56.

Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ et al (2013) Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36(12):4015–4021. https://doi.org/10.2337/dc13-0663CrossRefPubMedPubMedCentral

57.

White JL, Buchanan P, Li J, Frederich R (2014) A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. BMC Endocr Disord 14:17. https://doi.org/10.1186/1472-6823-14-17CrossRefPubMedPubMedCentral

58.

Fonseca V, Zhu T, Karyekar C, Hirshberg B (2012) Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab 14(4):365–371. https://doi.org/10.1111/j.1463-1326.2011.01553.xCrossRefPubMed

59.

Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ (2012) Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 28(9):1465–1474. https://doi.org/10.1185/03007995.2012.714360CrossRefPubMed

60.

Pratley RE, Fleck P, Wilson C (2014) Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab 16(7):613–621. https://doi.org/10.1111/dom.12258CrossRefPubMed

61.

Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM (2015) Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab 17(6):591–598. https://doi.org/10.1111/dom.12460CrossRefPubMed

62.

Ji LN, Han P, Wang XY, Liu JD, Zheng SX, Jou YM et al (2016) Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diabetes Investig 7(5):727–736. https://doi.org/10.1111/jdi.12511CrossRefPubMedPubMedCentral

63.

Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56(12):2582–2592. https://doi.org/10.1007/s00125-013-3039-1CrossRefPubMedPubMedCentral

64.

Wilding JPH, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A (2013) Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 15(5):403–409. https://doi.org/10.1111/dom.12038CrossRefPubMed

65.

Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC et al (2014) Empagliflozin as Add-On to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37(6):1650–1659. https://doi.org/10.2337/dc13-2105CrossRefPubMed

66.

Merker L, Haring HU, Christiansen AV, Roux F, Salsali A, Kim G et al (2015) Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med 32(12):1555–1567. https://doi.org/10.1111/dme.12814CrossRefPubMed

67.

Roden M, Weng JP, Eilbracht J, Delafont B, Kim G, Woerle HJ et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1(3):208–219. https://doi.org/10.1016/S2213-8587(13)70084-6CrossRefPubMed

68.

Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G et al (2015) Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol 14:154. https://doi.org/10.1186/s12933-015-0314-0CrossRefPubMedPubMedCentral

69.

ClinicalTrials.gov (2017) Safety and efficacy of empagliflozin (BI 10773) and sitagliptin versus placebo over 76 weeks in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01289990. Accessed 10 Dec 2017

70.

Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K (2012) Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 14(10):927–936. https://doi.org/10.1111/j.1463-1326.2012.01620.xCrossRefPubMed

71.

ClinicalTrials.gov (2017) An efficacy, safety, and tolerability study of canagliflozin in the treatment of patients with type 2 diabetes mellitus with inadequate glycemic control on metformin monotherapy. https://clinicaltrials.gov/ct2/show/NCT01340664. Accessed 10 Dec 2017

72.

Lewin A, DeFronzo RA, Patel S, Liu DC, Kaste R, Woerle HJ et al (2015) Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38(3):394–402. https://doi.org/10.2337/dc14-2365CrossRefPubMed

73.

DeFronzo RA, Lewin A, Patel S, Liu DC, Kaste R, Woerle HJ et al (2015) Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38(3):384–393. https://doi.org/10.2337/dc14-2364CrossRefPubMed

74.

Lu CH, Min KW, Chuang LM, Kokubo S, Yoshida S, Cha BS (2016) Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig 7(3):366–373. https://doi.org/10.1111/jdi.12422CrossRefPubMed

75.

ClinicalTrials.gov (2017) Comparison of fasiglifam (TAK-875) to placebo and sitagliptin in combination with metformin in participants with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01549964. Accessed 10 Dec 2017

76.

Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B et al (2015) Dual Add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38(3):376–383. https://doi.org/10.2337/dc14-1142CrossRefPubMed

77.

ClinicalTrials.gov (2017) A 16 weeks study on efficacy and safety of two doses of empagliflozin (BI 10773) (once daily versus twice daily) in patients with type 2 diabetes mellitus and preexisting metformin therapy. https://clinicaltrials.gov/ct2/show/NCT01649297. Accessed 10 Dec 2017

78.

ClinicalTrials.gov (2017) Comparison study of the glycemic effects, safety, and tolerability of exenatide once weekly suspension to sitagliptin and placebo in subjects with type 2 diabetes mellitus (DURATION-NEO-2). https://clinicaltrials.gov/ct2/show/NCT01652729. Accessed 10 Dec 2017

79.

Mu YM, Pan CY, Fan B, Hehnke U, Zhang XZ, Zhang XJ et al (2017) Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naive Asian patients with type 2 diabetes. Diabetes Res Clin Pract 124:48–56. https://doi.org/10.1016/j.diabres.2016.11.026CrossRefPubMed

80.

ClinicalTrials.gov (2017) Safety and efficacy study of empagliflozin and metformin for 24 weeks in treatment naive patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01719003. Accessed 10 Dec 2017

81.

ClinicalTrials.gov (2017) A study to evaluate the safety, tolerability, and efficacy of the addition of omarigliptin (MK-3102) to participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin therapy (MK-3102-024). https://clinicaltrials.gov/ct2/show/NCT01755156. Accessed 10 Dec 2017

82.

Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G et al (2016) Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 39(3):353–362. https://doi.org/10.2337/dc15-1736CrossRefPubMed

83.

Bailey TS, Takacs R, Tinahones FJ, Rao PV, Tsoukas GM, Thomsen AB et al (2016) Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab 18(12):1191–1198. https://doi.org/10.1111/dom.12736CrossRefPubMedPubMedCentral

84.

Schweizer A, Dejager S, Bosi E (2009) Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 11(8):804–812. https://doi.org/10.1111/j.1463-1326.2009.01051.xCrossRefPubMed

85.

Schweizer A, Couturier A, Foley JE, Dejager S (2007) Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 24(9):955–961. https://doi.org/10.1111/j.1464-5491.2007.02191.xCrossRefPubMed

86.

Bryson A, Jennings PE, Deak L, Paveliu FS, Lawson M (2016) The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension. Expert Opin Pharmacother 17(10):1309–1316. https://doi.org/10.1080/14656566.2016.1190334CrossRefPubMed

87.

Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ et al (2015) Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 17(3):309–312. https://doi.org/10.1111/dom.12424CrossRefPubMedPubMedCentral

88.

Pan C, Xing X, Han P, Zheng S, Ma J, Liu J et al (2012) Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 14(8):737–744. https://doi.org/10.1111/j.1463-1326.2012.01593.xCrossRefPubMed

89.

Goodman M, Thurston H, Penman J (2009) Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. horm metab res 41(5):368–373. https://doi.org/10.1055/s-0028-1104604CrossRefPubMed

90.

Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A (2016) Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4(3):211–220. https://doi.org/10.1016/s2213-8587(15)00417-9CrossRefPubMed

91.

Nauck M (2016) Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18(3):203–216. https://doi.org/10.1111/dom.12591CrossRefPubMedPubMedCentral

92.

Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13(1):7–18. https://doi.org/10.1111/j.1463-1326.2010.01306.xCrossRefPubMed

93.

Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg S et al (2019) Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the pioneer 2 trial. Diabetes Care. https://doi.org/10.2337/dc19-0883CrossRefPubMedPubMedCentral

94.

Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ (1998) Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41(3):271–278. https://doi.org/10.1007/s001250050903CrossRefPubMed

95.

Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A (2016) Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of medical care in diabetes. Ann Intern Med 164(8):542–552. https://doi.org/10.7326/M15-3016CrossRefPubMed

96.

Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Clinical Guidelines Committee of the American College of P (2017) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 166(4):279–290. https://doi.org/10.7326/M16-1860CrossRefPubMed

97.

Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29(1):46–52. https://doi.org/10.1007/BF02427280CrossRefPubMed

98.

Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S (2017) Early combination therapy with oral glucose-lowering agents in type 2 diabetes. Drugs 77(3):247–264. https://doi.org/10.1007/s40265-017-0694-4CrossRefPubMed

99.

Plosker G (2014) Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs 74(18):2191–2209. https://doi.org/10.1007/s40265-014-0324-3CrossRefPubMed

100.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2018) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract 24(1):91–120. https://doi.org/10.4158/CS-2017-0153CrossRefPubMed

101.

Okerson T, Yan P, Stonehouse A, Brodows R (2010) Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 23(3):334–339. https://doi.org/10.1038/ajh.2009.245CrossRefPubMed

102.

Bloomgarden Z (2017) Beyond HbA1c. J Diabetes 9(12):1052–1053. https://doi.org/10.1111/1753-0407.12590CrossRefPubMed

103.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 29(12):2638–2643. https://doi.org/10.2337/dc06-0706CrossRefPubMed

Title: Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis
Authors: Shubing Jia
Zhiying Wang
Ruobing Han
Zinv Zhang
Yuping Li
Xiaotong Qin
Mingyi Zhao
Rongwu Xiang
Jingyu Yang
Publication date: 01-01-2021
Publisher: Springer Milan
Keywords: Incretin Mimetics
Metformin
Hypoglycemia
Incretin Mimetics
Type 2 Diabetes
Published in: Acta Diabetologica / Issue 1/2021
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-020-01542-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Relative handgrip strength is inversely associated with the presence of type 2 diabetes in overweight elderly women with varying nutritional status

The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis

Barriers and facilitators to accessing insulin pump therapy by adults with type 1 diabetes mellitus: a qualitative study

One hundred years ago: the dawning of the insulin era

Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations

Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage